Encouraged by these findings, a clinical trial investigating the combination of anti-GD2 (dinutuximab) and anti-CD47 (magrolimab) antibodies in neuroblastoma relapse patients was initiated (NCT04751383). This evidence concerns the gene CD47 and neuroblastoma.